Pazopanib (GW-786034)

Catalog No. A11518

Pazopanib (GW-786034)是VEGFR-1,VEGFR-2,VEGFR-3,PDGFR-a/β和c-kit的有效且选择性的多靶点酪氨酸激酶抑制剂,可阻止肿瘤生长并抑制血管生成。
  • Koide H, .et al. Substrate-dependent effects of molecular-targeted anticancer agents on activity of organic anion transporting polypeptide 1B1, Xenobiotica, 2018, Oct;48(10):1059-1071 PMID: 29034773
  • Ellawatty WEA, .et al. Organic cation transporter 1 is responsible for hepatocellular uptake of the tyrosine kinase inhibitor pazopanib, Drug Metab Dispos, 2018, Jan;46(1):33-40 PMID: 29089306
  • Fujita KI, .et al. Involvement of the Transporters P-Glycoprotein and Breast Cancer Resistance Protein in Dermal Distribution of the Multikinase Inhibitor Regorafenib and Its Active Metabolites, J Pharm Sci, 2017, Sep;106(9):2632-2641 PMID: 28479358
Catalog Num A11518
M. Wt 437.5
Formula C21H23N7O2S
Purity >98%
Storage at -20°C 3 years Powder
CAS No. 444731-52-6
Synonyms GW 786034, Votrient,GW786034
SMILES CC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N
Pazopanib (GW-786034)是VEGFR-1,VEGFR-2,VEGFR-3,PDGFR-a/β和c-kit的有效且选择性的多靶点酪氨酸激酶抑制剂,可阻止肿瘤生长并抑制血管生成。
Targets
Target Value
VEGFR1IC50: 10nM
VEGFR2IC50: 30nM
VEGFR3IC50: 47nM
FGFRIC50: 74nM
PDGFRIC50: 84nM
c-KitIC50: 140nM
c-FmsIC50: 146nM
In vitro DMSO Warmed: 84 mg/mL (191.98 mM)
Water Insoluble
Ethanol Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
0.1 mM 22.86 mL 114.29 mL 228.57 mL
0.5 mM 4.57 mL 22.86 mL 45.71 mL
1 mM 2.29 mL 11.43 mL 22.86 mL
5 mM 0.46 mL 2.29 mL 4.57 mL

*The above data is based on the productmolecular weight 437.5 . Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.